| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Pemigatinib (JAN/USAN/INN); Pemazyre (TN) | ||||||
| Product | PEMAZYRE (Incyte Corporation) | ||||||
| Formula | C24H27F2N5O4 | ||||||
| Exact mass | 487.2031 | ||||||
| Mol weight | 487.4991 | ||||||
| Structure |  | ||||||
| Class | Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG03208 FGFR inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Antineoplastic, Receptor tyrosine kinase inhibitor | ||||||
| Disease | Cholangiocarcinoma (FGFR2 fusion positive) [DS:H00046] | ||||||
| Target | FGFR2* (CD332) [HSA_VAR:2263v2] [HSA:2263] [KO:K05093] FGFR1 (CD331) [HSA:2260] [KO:K04362] FGFR3 (CD333) [HSA:2261] [KO:K05094] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors L01EN02 Pemigatinib D11417 Pemigatinib (JAN/USAN/INN) <JP/US> Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D11417 Pemigatinib (JAN/USAN/INN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor DG03208 FGFR inhibitor D11417 Pemigatinib Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D11417 Pemigatinib Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) FGFR family FGFR1 (CD331) D11417 Pemigatinib (JAN/USAN/INN) <JP/US> FGFR2* (CD332) [HSA_VAR:2263v2] D11417 Pemigatinib (JAN/USAN/INN) <JP/US> FGFR3 (CD333) D11417 Pemigatinib (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11417 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11417 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11417 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11417 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11417 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D11417 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 35 1 C8y C 18.2000 -16.5900 2 C8x C 18.2000 -17.9900 3 N5x N 17.0100 -18.6900 4 C8y C 15.7500 -17.9900 5 C8y C 15.7500 -16.5900 6 C8y C 17.0100 -15.8900 7 C8x C 14.4200 -16.1700 8 C8y C 13.5800 -17.2900 9 N4x N 14.4200 -18.4100 10 C1b C 12.1800 -17.2900 11 N1y N 11.4800 -16.1000 12 C1x C 12.1800 -14.9100 13 C1x C 11.4800 -13.6500 14 O2x O 10.0800 -13.6500 15 C1x C 9.3800 -14.8400 16 C1x C 10.0800 -16.1000 17 C1x C 19.4600 -15.8900 18 N1y N 19.4600 -14.4900 19 C5x C 18.2700 -13.7900 20 N1y N 17.0100 -14.4900 21 C1b C 15.8200 -13.7900 22 C1a C 14.5600 -14.4900 23 O5x O 18.2700 -12.3900 24 C8y C 20.6500 -13.7900 25 C8y C 21.9100 -14.4200 26 C8y C 23.0300 -13.7200 27 C8x C 23.0300 -12.3200 28 C8y C 21.8400 -11.6200 29 C8y C 20.6500 -12.3900 30 O2a O 24.2200 -14.4200 31 C1a C 25.4100 -13.7200 32 O2a O 21.8400 -10.2200 33 C1a C 20.5800 -9.5200 34 X F 21.9100 -15.8200 35 X F 19.4600 -11.6900 BOND 39 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 5 7 1 8 7 8 2 9 8 9 1 10 4 9 1 11 8 10 1 12 10 11 1 13 11 12 1 14 12 13 1 15 13 14 1 16 14 15 1 17 15 16 1 18 11 16 1 19 1 17 1 20 17 18 1 21 18 19 1 22 19 20 1 23 6 20 1 24 20 21 1 25 21 22 1 26 19 23 2 27 18 24 1 28 24 25 2 29 25 26 1 30 26 27 2 31 27 28 1 32 28 29 2 33 24 29 1 34 26 30 1 35 30 31 1 36 28 32 1 37 32 33 1 38 25 34 1 39 29 35 1 |